Table 2 Summary of tumor response

From: Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Response, n (%)

RET fusion–positive solid tumors (n = 23)a

ORRb (95% CI)

13 (57) (35–77)

 CR

3 (13)

 PR

10 (43)

SD

6 (26)

PD

4 (17)

CBRc (95% CI)

16 (70) (47–87)

DCRd (95% CI)

19 (83) (61–95)

Median DOR, months (95% CI)e

11.7 (5.5–19.0)

  1. Response rates and the number of patients with each individual response per RECIST version 1.1 in the efficacy-evaluable population (n = 23). Two-sided 95% CIs were based on exact binomial distributions using the Clopper–Pearson method. aEnrollment as of 18 February 2021 and data cutoff date 18 October 2021. Excludes three patients (two with colon cancer and one with cholangiocarcinoma) with additional driver mutations (KRAS, PIK3CB and BRAF). bConfirmed CR or PR. cConfirmed CR, PR or SD ≥16 weeks. dConfirmed CR, PR or SD. eKaplan–Meier estimated.
Back to article page